Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Rheumatology (Oxford). 2024 Feb 1;63(2):277-284. doi: 10.1093/rheumatology/kead417.
The relationship between FMF and pregnancy outcomes remains unclear. This systematic review and meta-analysis aimed to clarify this association.
Electronic databases-PubMed, Web of Science, Cochrane, and EMBASE-were searched on 20 December 2022, using specific search terms. Case-control, cohort, and randomized clinical trial studies comparing patients with FMF and healthy controls were considered eligible. We excluded systematic reviews, meta-analyses, case series with fewer than five cases, republished articles without new findings on pregnancy outcomes, studies targeting paternal FMF, and those not published in English. The results were summarized in the form of odds ratios (ORs) and 95% CIs, using a random-effects model. This study was registered in the University hospital Medical Information Network Clinical Trials Registry (Japan) as UMIN000049827.
The initial electronic search identified 611 records, of which 9 were included in this meta-analysis (177 735 pregnancies, 1242 with FMF, and 176 493 healthy controls). FMF was significantly associated with increased odds of preterm deliveries (OR, 1.67; 95% CI, 1.05-2.67; I2 = 22%) and insignificantly associated with increased odds of fetal growth restriction (OR, 1.45; 95% CI, 0.90-2.34; I2 = 0%) and hypertensive disorders during pregnancy (OR, 1.28; 95% CI, 0.87-1.87; I2 = 0%).
FMF was significantly associated with preterm delivery and insignificantly associated with fetal growth restriction and hypertensive disorders. All of the included studies were observational studies. Treatment characteristics were not fully collected from the articles, and further analysis of treatments for FMF in pregnancy is still warranted.
FMF 与妊娠结局之间的关系尚不清楚。本系统评价和荟萃分析旨在阐明这种关联。
2022 年 12 月 20 日，通过特定的检索词，在电子数据库 PubMed、Web of Science、Cochrane 和 EMBASE 中进行了检索。纳入了比较 FMF 患者和健康对照组的病例对照、队列和随机临床试验研究。我们排除了系统评价、荟萃分析、病例系列研究（少于 5 例）、无妊娠结局新发现的重复发表文章、针对父亲 FMF 的研究以及未以英文发表的研究。结果以比值比（OR）和 95%置信区间（CI）的形式汇总，使用随机效应模型。该研究在日本大学医院医疗信息网络临床试验注册中心（UMIN000049827）注册。
最初的电子检索共确定了 611 条记录，其中 9 条被纳入荟萃分析（177735 例妊娠，1242 例 FMF，176493 例健康对照组）。FMF 与早产的几率增加显著相关（OR，1.67；95%CI，1.05-2.67；I2=22%），与胎儿生长受限的几率增加不显著相关（OR，1.45；95%CI，0.90-2.34；I2=0%），与妊娠高血压疾病的几率增加不显著相关（OR，1.28；95%CI，0.87-1.87；I2=0%）。
FMF 与早产显著相关，与胎儿生长受限和妊娠高血压疾病不显著相关。所有纳入的研究均为观察性研究。文章未充分收集 FMF 治疗的特征，仍需要进一步分析 FMF 在妊娠中的治疗。
